RIGL Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 34.53%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 25.2%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.60, signalling upside risk potential of 44.5%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.57 which suggests that it could grow by 38.95%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Catalyst Pharmaceuticals, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Catalyst Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.111, which suggesting that the stock is 11.137% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.735, suggesting its less volatile than the S&P 500 by 26.455%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Catalyst Pharmaceuticals, Inc. quarterly revenues of $152.6M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.7M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.79x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.33x versus 5.38x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ironwood Pharmaceuticals, Inc. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of -4.77%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.60, signalling upside risk potential of 44.5%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $5.35 which suggests that it could grow by 46.18%. Given that Ironwood Pharmaceuticals, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Ironwood Pharmaceuticals, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.111, which suggesting that the stock is 11.137% more volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.172, suggesting its less volatile than the S&P 500 by 82.759%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are larger than Ironwood Pharmaceuticals, Inc. quarterly revenues of $47.7M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is higher than Ironwood Pharmaceuticals, Inc.'s net income of -$2.3M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.79x while Ironwood Pharmaceuticals, Inc.'s PE ratio is 30.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.33x versus 2.09x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of 34.4%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Eli Lilly & Co.'s return on equity of 104.39%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.60, signalling upside risk potential of 44.5%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,214.34 which suggests that it could grow by 18.82%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Rigel Pharmaceuticals, Inc. has a beta of 1.111, which suggesting that the stock is 11.137% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.61% to investors and pays a quarterly dividend of $1.73 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.79x while Eli Lilly & Co.'s PE ratio is 45.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.33x versus 14.28x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 40.17% compared to Rigel Pharmaceuticals, Inc.'s net margin of -301.29%. Rigel Pharmaceuticals, Inc.'s return on equity of 273.99% beat Nektar Therapeutics's return on equity of -327.67%.

Rigel Pharmaceuticals, Inc. has a consensus price target of $51.60, signalling upside risk potential of 44.5%. On the other hand Nektar Therapeutics has an analysts' consensus of $129.86 which suggests that it could grow by 97.05%. Given that Nektar Therapeutics has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Rigel Pharmaceuticals, Inc..

Rigel Pharmaceuticals, Inc. has a beta of 1.111, which suggesting that the stock is 11.137% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.126%.

Rigel Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals, Inc. quarterly revenues are $69.5M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Rigel Pharmaceuticals, Inc.'s net income of $27.9M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Rigel Pharmaceuticals, Inc.'s price-to-earnings ratio is 5.79x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals, Inc. is 2.33x versus 67.95x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.